Pharmacokinetics of dexamethasone and valspodar, a P-glycoprotein (mdr1) modulator: Implications for coadministration

Pharmacotherapy

Volumn 18, Issue 6 I, 1998, Pages 1230-1236

  Kovarik, John M ^a   Purba, Harpal S ^a   Pongowski, Michele ^a   Gerbeau, Christophe ^a   Humbert, Henri ^a   Mueller, Edgar A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CYCLOSPORIN; CYTOCHROME P450; DEXAMETHASONE; GLYCOPROTEIN P; VALSPODAR; VERAPAMIL;

AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BIOTRANSFORMATION; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG SAFETY; DRUG SCREENING; FEMALE; HUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; STATISTICAL ANALYSIS;

ADULT; ANTIEMETICS; AREA UNDER CURVE; CROSS-OVER STUDIES; CYCLOSPORINS; DEXAMETHASONE; DRUG INTERACTIONS; EXTREMITIES; HUMANS; LINEAR MODELS; MALE; P-GLYCOPROTEIN; PARESTHESIA;

EID: 0031755807     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Sikic BI. Modulation of multidrug resistance: at the threshold. J Clin Oncol 1993;11:1629-35.
2. Bradley G, Juranka PF, Ling V. Mechanisms of multidrug resistance. Biochim Biophys Acta 1988;948:87-128.
3. Gaveriaux C, Boesch D, Jachez B, Bollinger P, Payne T, Loor F. SDZ PSC 833, a non-immunosuppressive cyclosporin analog, is a very potent multidrug-resistance modifier. J Cell Pharmacol 1991;2:225-34.
4. Boesch D, Gareriaux C, Jachez B, Pourtier-Mandanedo A, Bollinger P, Loor F. In vivo circumvention of P-gp-mediated multidrug resistance of tumour cells with SDZ PSC 833. Cancer Res 1991;51:4226-33.
5. Twentyman PR, Bleehen NM. Resistance modification by SDZ PSC 833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 1991;27:1639-42.
6. Boote DJ, Dennis IF, Twentymann PR, et al. A phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance. J Clin Oncol 1996;14:610-18.
7. Sonneveld P, Marie JP, Huisman C, et al. Reversal of multidrug resistance by SDZ PSC 833 combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 1996;10: 1741-50.
8. Cersosimo RJ, Karp DD. Adrenal corticosteroids as antiemetics during cancer chemotherapy. Pharmacotherapy 1986;6: 118-27.
9. Tsuei SE, Moore RG, Ashley JJ, McBride WG. Disposition of synthetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults. J Pharmacokinet Biopharm 1979;7:249-64.
10. Pichard L, Fabre I, Fabre G, et al. Cyclosporin A drug interactions: screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 1990;18:595-606.
11. Schinkel AH, Wagenaar E, van Deemter L, et al. Absence of the mdrla P-glycoprotein affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96:1698-1705.
12. Öst L, Klintmalm G, Ringdén O. Mutual interaction between prednisolone and cyclosporine in renal transplant patients. Transplant Proc 1985;17:1252-5.
13. Rogerson ME, Marsden JT, Reid KE, Bewick M, Holt DW. Cyclosporine blood concentrations in the management of renal transplant recipients. Transplantation 1986;41:276-8.
14. Ptachcinski RJ, Venkataramanan R, Burckart GJ, et al. Cyclosporine-high-dose steroid interaction in renal transplant recipients: assessment by HPLC. Transplant Proc 1987;19: 1728-9.
15. Hrick DE, Moritz C, Mayes JT, Schulak JA. Association of the absence of steroid therapy with increased cyclosporine blood levels in renal transplant recipients. Transplantation 1990;49: 221-3.
16. Rocci ML, Tieze KJ, Lee J, Harris H, Danziesen J, Burke JF. The effect of cyclosporine on the pharmacokinetic of prednisolone in renal transplant patients. Transplantation 1988;45:656-60.
17. Frey FJ, Schnetzer A, Horber FF, Frey BM. Evidence that cyclosporine does not affect the metabolism of prednisolone after renal transplantation. Transplantation 1987;43:494-8.
18. Langhoff E, Madsen S, Flachs H, Olgaard K, Ladefoged J, Hvidberg EF. Inhibition of prednisolone metabolism by cyclosporine in kidney-transplant patients. Transplantation 1985;39:107-9.
19. Kovarik JM, Mueller EA, Richard F, Tetzloff W. Optimizing the absorption of valspodar, a P-glycoprotein modulator. II. Quantifying its pharmacokinetic variability and refining the bioavailability estimate. J Clin Pharmacol 1997;37:1009-14.
20. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657-80.
21. Mueller EA, Kovarik JM, Ueresin Y, et al. Optimizing the absorption of valspodar, a P-glycoprotein modulator. I. Selecting an oral formulation and exploring its clinical pharmacokinetics/dynamics. J Clin Pharmacol 1997;37: 1001-8.
22. Urso R, Aarons L. Bioavailability of drugs with long elimination half-lives. Eur J Clin Pharmacol 1983;25:689-93.
23. Duggan DE, Yeh KC, Matalia N, Ditzler CA, McMahon FG. Bioavailability of oral dexamethasone. Clin Pharmacol Ther 1975;18:205-9.
24. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Tastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-8.
25. Brady ME, Sartiano GP, Rosenblum SL, Zaglama NE, Bauguess CT. The pharmacokinetics of single high doses of dexamethasone in cancer patients. Eur J Clin Pharmacol 1987;32:593-6.